Evidence map›Paper›PMID 27803172›Full record

ArticleThe Journal of infectious diseases2016

Type I Interferon is Pathogenic During Chronic Mycobacterium africanum Infection.

Kirsten E Wiens, Joel D Ernst

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Experimental Evidence for LimitedFrontiers in microbiology · 2019
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kirsten E WiensDepartment of Pathology.
Joel D ErnstDepartment of Pathology.
New York University · US

Funding

Initiation of the Immune Response to M. tuberculosisR01AI051242 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ERNST, JOEL D. · 2002 to 2019
$8.3M
Type I Interferons in Immunity to TuberculosisR01AI059667 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ERNST, JOEL D. · 2004 to 2008
$2.0M
NIAID NIH HHS R01 AI051242NIAID NIH HHS R01 AI059667
6 · The paper itself

Abstract

Type I interferons (IFNs, including IFN-αβ) contribute to the pathogenesis of Mycobacterium tuberculosis strains that induce high IFN-αβ levels. In the current study we examined the role of IFN-αβ during infection with a Mycobacterium africanum strain that induces low IFN-β levels. We infected wild-type and IFN-αβ receptor knockout mice with M. africanum and monitored bacterial growth, lung disease, and survival over 292 days. We found reduced lung bacterial burdens and less severe histopathological findings in the absence of IFN-αβ signaling. We conclude that IFN-αβ is pathogenic during chronic M. africanum infection and that the pathogenic effects may be mediated through poorer control of bacterial growth.

Indexed as

AnimalsBacterial LoadChronic DiseaseDisease Models, AnimalHistocytochemistryInterferon Type ILungMaleMice, Inbred C57BLMice, KnockoutMycobacteriumReceptors, InterferonSurvival AnalysisTuberculosis, PulmonaryInterferon Type IReceptors, InterferonIFN-αβMycobacterium africanumtuberculosistype I interferon

Identifiers

PMID27803172
PMCPMC5142099
OpenAlexW2548459922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.